|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||17.75 - 18.23|
|52 Week Range||5.75 - 28.25|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Valneva's (VALN) shares surge after its COVID vaccine demonstrates superiority over AstraZeneca's COVID vaccine in a phase III study.
These COVID-19 vaccine developers are all moving in response to strong late-stage results for Valneva's VLA2001.
Stocks have bounced back sharply in the past week, and so it's reasonable for market participants to take a slight pause coming into Monday morning's open. As of 8:30 a.m. EDT, futures on the Nasdaq Composite (NASDAQINDEX: ^IXIC) were down about a quarter percent, which was in line with the broader stock market. Valneva (NASDAQ: VALN) saw its shares move strongly higher in premarket trading Monday morning, while the news was bad for industry peer Revance Therapeutics (NASDAQ: RVNC).